Ginkgo Bioworks (US:DNA) ZACKS·2025-05-06 23:30Core Insights - Ginkgo Bioworks Holdings, Inc. reported a quarterly loss of $1.58 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.23, marking an earnings surprise of -28.46% [1] - The company generated revenues of $48.32 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 17.12% and showing a year-over-year increase from $37.94 million [2] - Ginkgo Bioworks shares have declined approximately 29.5% year-to-date, contrasting with the S&P 500's decline of -3.9% [3] Company Performance - Over the last four quarters, Ginkgo Bioworks has surpassed consensus EPS estimates only once, indicating inconsistent performance [2] - The current consensus EPS estimate for the upcoming quarter is -$0.47 on revenues of $44.55 million, and for the current fiscal year, it is -$3.72 on revenues of $171.48 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Ginkgo Bioworks belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Ginkgo Bioworks' stock performance [5][6]